What Does "IRB-Approved" Actually Mean? Why It Isn't the Same as FDA Approval

What This Article Covers

Clinics marketing unproven stem cell treatments frequently describe their offering as part of an "IRB-approved study" to sound rigorously vetted and officially sanctioned. This article explains what an Institutional Review Board (IRB) is actually required to evaluate, what it is not designed or empowered to confirm, how that gap has been documented and exploited in the stem cell marketplace, and concrete ways to tell a legitimate FDA-regulated trial from marketing language that borrows an ethics committee's name for credibility.

What an IRB Is Actually For

IRBs exist because of federal human-subjects protection rules — the "Common Rule" at 45 CFR 46 and FDA's parallel regulation at 21 CFR 56 — which require that any institution conducting human research have a committee review a study before it enrolls people. Under the federal criteria for IRB approval (45 CFR 46.111), a board must find that risks to participants are minimized and reasonable relative to anticipated benefits, that selection of subjects is equitable, that informed consent will be properly sought and documented, and, where appropriate, that there are adequate provisions for monitoring data and protecting participant privacy. FDA's own guidance on IRBs describes their job as overseeing the ethical conduct of a study and safeguarding participants' rights and welfare throughout — a distinct function from the scientific or regulatory review that determines whether a product itself works.

What "IRB-Approved" Does Not Mean

• It does not mean the treatment has been proven safe.
• It does not mean the treatment has been proven effective.
• It does not mean the FDA authorized or is even aware of the study. For most cell-based products intended to treat disease, a separate Investigational New Drug (IND) application and FDA clearance is required before human testing — a step some clinics skip entirely.
• It does not mean independent scientists validated the study's hypothesis or design for soundness; the IRB's job is ethical acceptability of the protocol as submitted, not a verdict on its scientific merit.
• It is not a uniform government stamp. IRBs can be hospital-based, university-based, or independent commercial boards, and "an IRB approved this" says nothing about that particular board's rigor or independence from the clinic it's reviewing.

Why the Phrase Shows Up in Clinic Marketing

Direct-to-consumer stem cell businesses have long advertised procedures as performed "under an IRB-approved protocol," sometimes charging patients substantial fees to enroll as "subjects" in that very study — the reverse of how most legitimate trials work. Stem-cell biologist Paul Knoepfler has documented cases of loosely affiliated, clinic-friendly IRBs approving high-risk, fee-for-participation studies of unapproved fat-derived stem cell injections, and argued the FDA needed to act against this pattern. Separately, in 2018 Senator Chuck Grassley sent formal oversight letters to HHS and the FDA raising concerns about businesses marketing unproven, pay-to-participate procedures as "clinical trials" — including scrutiny connected to a stem cell injection product tied to reports of patients being blinded — and pressed the agencies on how such studies and their IRBs were actually being overseen.

How to Tell a Legitimate FDA Trial from Marketing Language

• Ask whether the study operates under an active IND; a genuine FDA-regulated cell-therapy trial for a drug or biologic requires one, and a legitimate site should be able to discuss it.
• Independently look up any registration on ClinicalTrials.gov rather than taking a clinic's printed number or description at face value.
• Ask who pays whom: in many federally funded or sponsor-run trials, participants are not charged thousands of dollars to receive the investigational product itself; being asked to pay to be a "research subject" is worth extra scrutiny.
• Ask which specific IRB reviewed the protocol, and look for information about that board independent of the clinic's own marketing.
• Treat "IRB-approved" as a process claim, not an outcomes claim, and ask a separate question: what published, peer-reviewed data shows this specific product is safe and effective for your condition?

Bottom Line

"IRB-approved" sounds like an official safety seal, but it describes an ethics-and-procedure review — not a verdict on whether a treatment works or is safe for a given patient. The step that specifically evaluates a planned human use of an investigational cell-based product is an IND review, and the step that confirms a product has met the legal bar for safety and effectiveness is FDA approval or licensure. When marketing leads with "IRB-approved" instead of information about IND status or supporting data, that word choice itself is worth questioning.